Biomm S.A. (BVMF:BIOM3)

Brazil flag Brazil · Delayed Price · Currency is BRL
7.54
+0.19 (2.59%)
Apr 28, 2026, 5:05 PM GMT-3
-25.64%
Market Cap 1.03B
Revenue (ttm) 269.30M
Net Income (ttm) -6.69M
Shares Out 136.84M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 64,600
Average Volume 2,154,320
Open 7.47
Previous Close 7.35
Day's Range 7.37 - 7.54
52-Week Range 5.75 - 10.66
Beta 0.52
RSI 52.28
Earnings Date May 15, 2026

About Biomm

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; Lifepen G, a reusable insulin injection pen; and Biopemm, a reusable insulin delivery device for diabetic patients. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 130
Stock Exchange Brazil Stock Exchange
Ticker Symbol BIOM3
Full Company Profile

Financial Performance

In 2025, Biomm's revenue was 269.30 million, an increase of 88.45% compared to the previous year's 142.91 million. Losses were -6.69 million, -91.34% less than in 2024.

Financial Statements

News

There is no news available yet.